Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

KenFaulkenberry Mar. 14 at 2:23 PM

$ABBV Abbvie (ABBV) Stock Analysis AbbVie is a global, research-based biopharmaceutical company engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of AbbVie (ABBV)? https://dividendvaluebuilder.com/abbvie-abbv-dividend-stock-analysis/

0 · Reply

V9RDPUMA Mar. 14 at 1:54 PM

$ABBV WTF now?? No news other than an upgrade and it drops like rock??!! I’m out on next surge to 230. Rode this shit since the spinout from ABT, time to take the massive gain and move on.

1 · Reply

xtremdelt8 Mar. 13 at 11:16 PM

$ABBV Still trades like a fucking penny stock.

0 · Reply

Oldpuck Mar. 13 at 8:37 PM

$ABBV What is going on with this stock

0 · Reply

67X_ROI_Q1_2026 Mar. 13 at 7:09 PM

$SLS Aza+VEN - BAT for CONTROL Patients in the SLS P3 Just FAILED 2, PHASE 3 AML Remission Maintenance Trials conducted by $ABBV. - the VIALE - M and VIALE - T Phase 3 Trials were Terminated due to poor Enrollment resulting from Serious Toxicity. Meanwhile Gps has proven successful in all Previous Trials Including 2 Phase 2 AML Remission Trials, - in CR1 and CR2 with Statistically Significant MOS 2x and 4x Greater than the Standard of Care. it is not complicated. $XBI

0 · Reply

67X_ROI_Q1_2026 Mar. 13 at 6:29 PM

$SLS Gps Immunotherapy will revolutionize AML Remission Maintenance Treatment. - the Aza+VEN, VIALE-M - M for Maintenance, Phase 3 Trial for CR1 First Remission patients conducted by $ABBV- FAILED. - the Aza+VEN, VIALE-T - T for Transplant, Phase 3 Trial for Maintenance Phase 3 Trial for Post Transplant Patients conducted by $ABBV - also FAILED. - Aza+VEN is the BAT for Control Patients in the SLS REGAL Phase 3 Trial for Second Remission CR2/3 Patients This $6 stock will be $60 in An Instant and Climbing like Abvx did, the moment the Gps Ph3 Registrational Results are announced - they are coming, it is inevitable.

0 · Reply

DanishVikings Mar. 13 at 5:34 PM

$ABBV

0 · Reply

Quantumup Mar. 13 at 1:15 PM

Stifel⬆️ $ORKA's PT to $72 from $47 and reitertaed at Buy. $ABBV $JNJ - $PTGX $UCBJY Stifel said—ORKA now expects Ph2 psoriasis data from ORKA-001 in 2Q26 (from 2H26) -- enrollment completed December 2025. ORKA plans to share week-16 data while providing longer-term follow-up in 2H26 -- the prior guidance was to share both together. Bottom line, this update significantly moves up the timing of ORKA's first clinical readout, and we expect to see shares react favorably towards increased proximity to the update. In terms of bar for success, we think PASI100 rates in-line with Skyrizi (36-51%) would represent a win with potential for Q6M or yearly vs. Q3M dosing while we see prospective support for the exposure hypothesis from the KNOCKOUT study providing additional support for the upside hypothesis of Bimzelx-like responses (59%-68%). We see Base Case upside in the $50-$70 range; downside for inferior efficacy could see shares trade to $10-20 with a refocus towards ORKA-002.

0 · Reply

milans100 Mar. 13 at 6:42 AM

$VKTX Some research wrt $ABBV + Kailera I wonder if this is what's actually cooking :-(...

1 · Reply

leshgo Mar. 13 at 4:44 AM

$VKTX Agree that $ABBV is the most likely buyer for $VKTX. ⛔️ Personal opinion only. • Timeline Mismatch: ABBV is building obesity drug facilities targeting 2029, but their current pipeline won't meet that deadline. • US Focus: They committed to a massive $100B US investment. • The Alternatives: Late-stage options are mainly $VKTX & Kailera. Kailera’s China ties make them a less viable target. • M&A Appetite: ABBV CFO confirmed at Leerink that they have the cash and willingness to acquire the right asset. • Bottom line: Boasting both prominent injectable and oral pipelines, $VKTX is the ultimate M&A target.

3 · Reply

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

ABBV

Mar 9, 2026, 8:00 AM EDT - 5 days ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

ABBV

Mar 3, 2026, 8:00 AM EST - 11 days ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

ABBV

Mar 2, 2026, 8:30 AM EST - 12 days ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

ABBV

Feb 24, 2026, 8:00 AM EST - 18 days ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

ABBV

Feb 23, 2026, 12:03 PM EST - 19 days ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

ABBV

Feb 23, 2026, 11:00 AM EST - 19 days ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

ABBV

Feb 20, 2026, 2:00 AM EST - 23 days ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

ABBV

Feb 19, 2026, 9:37 AM EST - 23 days ago

AbbVie Declares Quarterly Dividend

ABBV

Feb 11, 2026, 6:49 PM EST - 4 weeks ago

AbbVie sues US health agency over Botox price controls

ABBV

Feb 11, 2026, 5:13 PM EST - 4 weeks ago

Abbvie sues US health agency over Botox

ABBV

Feb 4, 2026, 12:38 PM EST - 5 weeks ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

ABBV

Feb 4, 2026, 8:34 AM EST - 5 weeks ago

AbbVie Revenue Rises on Immunology Growth

ABBV

Feb 4, 2026, 8:18 AM EST - 5 weeks ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

ABBV

Feb 4, 2026, 7:51 AM EST - 5 weeks ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

ABBV

Feb 4, 2026, 7:48 AM EST - 5 weeks ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

ABBV

Feb 3, 2026, 8:50 AM EST - 5 weeks ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

ABBV

Feb 3, 2026, 8:00 AM EST - 5 weeks ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

ABBV

Jan 29, 2026, 8:00 AM EST - 6 weeks ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

ABBV

Jan 28, 2026, 8:00 AM EST - 6 weeks ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

ABBV

Jan 27, 2026, 4:52 PM EST - 6 weeks ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV LLY PFE

Jan 27, 2026, 9:34 AM EST - 6 weeks ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

ABBV

$AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jan 16, 2026, 1:43 PM EST - 2 months ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

ABBV

Jan 16, 2026, 1:35 PM EST - 2 months ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB ABBV

Jan 14, 2026, 2:01 PM EST - 2 months ago

AbbVie plans to build out its presence in obesity market

ABBV

Jan 13, 2026, 7:22 AM EST - 2 months ago

AbbVie reaches 3-year deal with White House to lower drug prices

ABBV

Jan 13, 2026, 5:24 AM EST - 2 months ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

ABBV

Jan 12, 2026, 7:03 PM EST - 2 months ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

ABBV

Jan 12, 2026, 6:57 PM EST - 2 months ago

Abbvie, US reach agreement to cut drug prices

ABBV

Jan 12, 2026, 6:30 PM EST - 2 months ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

ABBV

Jan 12, 2026, 7:39 AM EST - 2 months ago

AbbVie, RemeGen partner on experimental solid tumor treatment

ABBV

Jan 12, 2026, 7:30 AM EST - 2 months ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

ABBV

Jan 12, 2026, 6:00 AM EST - 2 months ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

ABBV WST

Jan 12, 2026, 6:00 AM EST - 2 months ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

ABBV WST

Jan 8, 2026, 7:38 AM EST - 2 months ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

ABBV RVMD

Jan 7, 2026, 2:58 PM EST - 2 months ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

ABBV RVMD

Jan 7, 2026, 2:48 PM EST - 2 months ago

AbbVie Near Deal for Revolution Medicines

ABBV RVMD

Jan 7, 2026, 8:00 AM EST - 2 months ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

ABBV

Jan 6, 2026, 11:43 AM EST - 2 months ago

What Can Trigger A Breakout In Abbvie Stock?

ABBV

Jan 6, 2026, 7:29 AM EST - 2 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ABBV ARGX NBIX

Jan 5, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

ABBV

Dec 19, 2025, 10:45 AM EST - 3 months ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD LLY MRK

Dec 17, 2025, 4:11 PM EST - 3 months ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY LLY NVS PFE

Dec 17, 2025, 2:17 PM EST - 3 months ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

ABBV MSFT NFLX TWLO

Dec 8, 2025, 1:30 AM EST - 3 months ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

ABBV

Dec 2, 2025, 8:15 AM EST - 3 months ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

ABBV

Nov 28, 2025, 7:01 AM EST - 3 months ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

ABBV

Nov 25, 2025, 9:30 AM EST - 3 months ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

ABBV

Nov 24, 2025, 8:00 AM EST - 3 months ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

ABBV

$AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma$

Nov 18, 2025, 12:47 PM EST - 4 months ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

ABBV

KenFaulkenberry Mar. 14 at 2:23 PM

0 · Reply

V9RDPUMA Mar. 14 at 1:54 PM

$ABBV WTF now?? No news other than an upgrade and it drops like rock??!! I’m out on next surge to 230. Rode this shit since the spinout from ABT, time to take the massive gain and move on.

1 · Reply

xtremdelt8 Mar. 13 at 11:16 PM

$ABBV Still trades like a fucking penny stock.

0 · Reply

Oldpuck Mar. 13 at 8:37 PM

$ABBV What is going on with this stock

0 · Reply

67X_ROI_Q1_2026 Mar. 13 at 7:09 PM

0 · Reply

67X_ROI_Q1_2026 Mar. 13 at 6:29 PM

0 · Reply

DanishVikings Mar. 13 at 5:34 PM

$ABBV

0 · Reply

Quantumup Mar. 13 at 1:15 PM

0 · Reply

milans100 Mar. 13 at 6:42 AM

$VKTX Some research wrt $ABBV + Kailera I wonder if this is what's actually cooking :-(...

1 · Reply

leshgo Mar. 13 at 4:44 AM

3 · Reply

truehealthvalue Mar. 12 at 9:07 PM

$ABBV take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position

0 · Reply

SunnySeed Mar. 12 at 7:33 PM

$SLS Damn $AMGN has way more cash than $ABBV not to mention their share price is over $300 who could it be??!!!

1 · Reply

IndyOne Mar. 12 at 5:11 PM

$MRNA Moderna’s mRNA 4157 (V940) combined with Keytruda delivered a durable 49% reduction in recurrence or death for Phase 2b melanoma results. Merck’s Keytruda pulled $31.7B in 2025 revenue. Keytruda’s patent clock is ticking and Merck can extend with mRNA-4157. The 49% RFS benefit holding at 5 years is rare in oncology. Most immunotherapy benefits erode over time. This one didn't. The 62% DMFS reduction is actually the stronger number and it's underreported. Follow the bread crumbs that show news coming on large partnership or buyout $JNJ $MRK $ABBV Will J&J, Merck, or AbbVie make the next move on Moderna's platform? Buy Moderna and hold. Then buy some more.

1 · Reply

Bagholding_VKTX Mar. 12 at 3:49 PM

$VKTX XBI is in freefall, and every pharma is down a lot (LLY, NVO, GPCR, MRK, PFE). Meanwhile, we will soon be turning green. And I also noticed $ABBV is following a similar pattern. I think we are not alone in thinking that ABBV has an interest in Viking. Institutions may also be thinking the same thing, as we can see here.

0 · Reply

67X_ROI_Q1_2026 Mar. 11 at 4:34 PM

$SLS $PFE $ABBV $BMY Big Pharma’s know. +/- 60 Events right now, Just from the Control Arm while we await 80. --- Let it Sink in... I keep asking all the Paid Short Lowlife Working here to find 1 Trial for AML Cr2 Patients, not getting transplant with Any meaningful Survival Past 12 months, or any Patients on BAT Remaining alive at ALL past 24 months --- CRICKETS.

0 · Reply

67X_ROI_Q1_2026 Mar. 11 at 4:07 PM

$SLS $ABBV $BMY Big Pharma’s know. +/- 60 Events right now, Just from the Control Arm while we await 80.

0 · Reply

67X_ROI_Q1_2026 Mar. 11 at 11:56 AM

$SLS $PFE $ABBV I keep asking all the Paid Short Lowlife Working here to find 1 Trial for AML Cr2 Patients, not getting transplant with Any meaningful Survival Past 12 months, or any Patients on BAT Remaining alive at ALL past 24 months --- CRICKETS

1 · Reply

TSGBrokers Mar. 11 at 10:58 AM

$ABBV Early Phase 1 data for ABBV-295 is a game changer. 9.8% weight loss in 12 weeks puts AbbVie squarely in the ring with the GLP-1 giants. 🥊 Beyond obesity, the 2026 guidance is rock solid: ✅ $67B Revenue target (9.5% growth) ✅ Skyrizi & Rinvoq offsetting Humira erosion ✅ Strong cash flow to fund more M&A The market is starting to price in the "New AbbVie." This isn't just an immunology play anymore—it's a diversified high-tech growth engine. Chart looking primed. 📈🔥 #ObesityDrug #BioTech #Dividends #BigPharma Risk Warning: CFDs are high-risk. 77.95% of retail accounts lose money.

1 · Reply

67X_ROI_Q1_2026 Mar. 11 at 6:29 AM

$SLS How do Big Pharma's Know Gps Works? $ABBV $BMY Conducted 2 Large Phase AML Remission Maintenance Trials - that RECENT FAILED. While we are seeing Miraculous Survival in ALL POOLED Phase 3 Patients, the Best Available Treatment (BAT) - Aza+VEN recently FAILED 3 Large Phase 3 Trials conducted by $ABBV - Including Failing 2 AML Remission Maintenance Trials. Everyone Knows Its Gps - GPs is doing what its done in all Previous Trials, prevent relapse and extend survival, including in 2 AML Remission Maintenance Phase 2 Trials.

1 · Reply

67X_ROI_Q1_2026 Mar. 11 at 6:22 AM

$SLS $ABBV Every SLS investor is Guaranteed Huge Returns - as the share price will continue to Climb as we wait for the IMMINENTLY Due Phase 3 Results. -- Could be Announced ANY DAY NOW and are worth every bit of $40B / $180 Per Share to Big Pharma. The Share Price Will Continue Climbing until it absolutely launches. - Just 2 errors in the attached Article re Valuation/ Cash - What is Truly INSANE and why SLS Shares May well be $10/$15 by Friday for the 10k--- the CASH ... The CASH, which had caused such an overhang on the Share Price in the Past - is NOW a Huge Catalyst +/-$100M will be Reported this week/next? and a TINY $6.2-$6.5M Burn... Runway into Infinity PLUS the KICKER -- SLS has nearly $400M on Deck. $4OO MILLION when you add in Remaining Warrant CASH AND $600M from Rare Priority Review Vouchers. link to full article reddit.com/r/sellasLifescience

2 · Reply

67X_ROI_Q1_2026 Mar. 11 at 6:09 AM

$SLS there have been an unusual amount of unconfirmed rumors, today. $PFE - SLS did terminate the entire direct commercialization team 2 years ago, pursuing partnerships and 'beyond'. - We know the Ceo disclosed there have been interested Pharma's, large and small. We know he's been negotiating. His quote at the time, he "would inform the public when he had SOMETHING CONCRETE". Exact quote. - the CFO GC 8K both Employment Contract Revised accelerating Option Vesting upon COC. CFO/GC's do all the internal Due Diligence work and essentially working themselves out of a Job. - there have been no HR moves to add for a Go It alone Strategy, this far along. P3 P2B, be managerial malpractice. - the lack of RSU's for CEO and GC - 56 day quiet period - No SLS009 Trial News --- very odd, as I've posted. 009 P2b Data was better than p1B data - worth $4.9B - Big Pharma's $ABBV $BMY Rhhby KNOW GPs works, BAT FAILED, would be willing to pay close to Ceo;s max value. https://www.youtube.com/watch?v=GRyZBZ2vXG0

2 · Reply

67X_ROI_Q1_2026 Mar. 10 at 10:34 PM

$SLS $ABBV Dr. Levy, the Director of Hematological Research at Baylor Med, Dr. Jamy and Dr. Tsirigotis - these Dr's treat 15% of the Enrolled Regal Trial Patients, and they are in lockstep, on the record stating Median Overall Survival for Patients on BAT is Dismal, Toxic, Extremely Poor, Not Durable - only 5-7 months, 6 to 7 months, 6-8 months - In Line with the Published Avalon Trial. Dr. Jamy was even asked, what was the longest survival he sees in his practice...

0 · Reply

Market Cap	388.43B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	21.97
Forward PE	15.43
Profit Margin	6.91%
Debt to Equity Ratio	-20.91

Volume	5,676,000
Avg Vol	7,099,788
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	1%
Beta	0.34
Analysts	Strong Sell
Price Target	$249.82